Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae3 hours ago
Covid-vaccine maker AstraZeneca said Friday that profits fell sharply in the first half on ballooning costs linked to its takeover of US biotech firm Alexion.
The pharmaceutical group added that sales of its Covid-19 vaccine Vaxzevria slumped 49 percent in the second quarter.
Net profit slumped 64 per cent to $746 million compared with the first six months of last year, AstraZeneca said in a statement.
Operating expenses jumped 33 per cent, “reflecting the addition of Alexion, and continued investment in new launches and the pipeline” of drugs, the group said.
That offset a 48-percent jump in revenue to more than $22 billion.
Revenue rose strongly thanks to sales of Alexion medicines.
The group said annual revenue from Covid-19 medicines is anticipated to be broadly flat compared with 2021.
Astra said the majority of Vaxzevria revenue this year was set to come from initial contracts struck as the pandemic took hold.
After initially offering the vaccine at cost, Astra is selling Vaxzevria — developed alongside University of Oxford — for profit.
Astra on Friday added that growth of its preventative antibody treatment Evusheld was offsetting an expected decline in Vaxzevria sales.
“We have made great progress in our efforts to combat Covid-19,” AstraZeneca chief executive Pascal Soriot said.
“Vaxzevria is estimated to have saved more than six million lives during the first year of roll-out, and Evusheld has protected hundreds of thousands of immunocompromised people, enabling them to return to a more normal life.”
Soriot added that “Evusheld continues to demonstrate activity against new variants”.
Widespread vaccination across the European Union, combined with the less deadly Omicron variant, have seen the levels of people being hospitalised or dying from Covid drop dramatically.
Overall, however, “pharma giant AstraZeneca has once again reported strong second quarter sales and earnings, driven by growth in oncology, or cancer treatments”, noted Keith Bowman, investment analyst at Interactive Investor.
“In all, ongoing investment costs in drug development continue to weigh.”
Bowman added that the purchase price of Alexion “is also yet to be fully justified, while sales in China are declining”.
AstraZeneca completed its takeover of Alexion for $39 billion in 2021.
Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.
In early London trading following the results, shares in AstraZeneca by dropped 2.1 percent. — AFP
Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae3 hours ago
10 lucky fans will have the once-in-a-lifetime chance to meet the eight-division world champion
uae attractions4 hours ago
ASAS 2024 brought together over 1,000 young talents from 50 nationalities under the theme 'Art and Innovation'
kt network5 hours ago
While President-elect Trump's administration originally filed the search case against Google during his first term, he indicated he might not break up the company
tech5 hours ago
The gathering explored the cutting edge of cinema, new media, PR and marketing, IT technologies, eSports, and game development
kt network5 hours ago
Passengers were currently being prevented from entering the building
world5 hours ago
Users will be able to select transcript language, too; here's how the new smart tool works
tech5 hours ago
With the new tariff, Yango Ride users can expect comfortable, modern limo vehicles starting from a minimum fare of Dh15.6
kt network6 hours ago